These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 25877475)
1. Corrigendum to "Tetrahydrobiopterin therapy vs phenylalanine-restricted diet: impact on growth in PKU" [Mol. Genet. Metab. 109 (2013) 331-338]. Aldámiz-Echevarría L; Bueno MA; Couce ML; Lage S; Dalmau J; Vitoria I; Andrade F; Llarena M; Blasco J; Alcalde C; Gil D; García MC; González-Lamuño D; Ruiz M; Ruiz MA; González D; Sánchez-Valverde F Mol Genet Metab; 2015 Mar; 114(3):485. PubMed ID: 25877475 [No Abstract] [Full Text] [Related]
2. Tetrahydrobiopterin therapy vs phenylalanine-restricted diet: impact on growth in PKU. Aldámiz-Echevarría L; Bueno MA; Couce ML; Lage S; Dalmau J; Vitoria I; Andrade F; Llarena M; Blasco J; Alcalde C; Gil D; García MC; González-Lamuño D; Ruiz M; Ruiz MA; González D; Sánchez-Valverde F Mol Genet Metab; 2013 Aug; 109(4):331-8. PubMed ID: 23810227 [TBL] [Abstract][Full Text] [Related]
3. Response of patients with phenylketonuria in the US to tetrahydrobiopterin. Matalon R; Michals-Matalon K; Koch R; Grady J; Tyring S; Stevens RC Mol Genet Metab; 2005 Dec; 86 Suppl 1():S17-21. PubMed ID: 16143554 [TBL] [Abstract][Full Text] [Related]
4. Potential role of tetrahydrobiopterin in the treatment of maternal phenylketonuria. Trefz FK; Blau N Pediatrics; 2003 Dec; 112(6 Pt 2):1566-9. PubMed ID: 14654666 [TBL] [Abstract][Full Text] [Related]
5. Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: a pilot study. Fiege B; Bonafé L; Ballhausen D; Baumgartner M; Thöny B; Meili D; Fiori L; Giovannini M; Blau N Mol Genet Metab; 2005 Dec; 86 Suppl 1():S91-5. PubMed ID: 16290003 [TBL] [Abstract][Full Text] [Related]
6. Corrigendum to "A glimpse into past, present, and future DNA sequencing" [Mol. Genet. Metab. 110 (2013) 3-24]. Morey M; Fernández-Marmiesse A; Castiñeiras D; Fraga JM; Couce ML; Cocho JA Mol Genet Metab; 2015 Mar; 114(3):484. PubMed ID: 25877474 [No Abstract] [Full Text] [Related]
7. Corrigendum to "Risk factors for developing mineral bone disease in phenylketonuric patients" [Mol. Genet. Metab. 108 (2013) 149-154]. Mirás A; Dolores Bóveda M; Leis MR; Mera A; Aldámiz-Echevarría L; Fernández-Lorenzo JR; Fraga JM; Couce ML Mol Genet Metab; 2015 Mar; 114(3):483. PubMed ID: 25877473 [No Abstract] [Full Text] [Related]
8. Corrigendum to "Clinical and metabolic findings in patients with methionine adenosyltransferase I/III deficiency detected by newborn screening" [Mol. Genet. Metab. 110 (2013) 218-221]. Couce ML; Dolores Bóveda M; García-Jimémez C; Balmaseda E; Vives I; Castiñeiras DE; Fernández-Marmiesse A; Fraga JM; Mudd SH; Corrales FJ Mol Genet Metab; 2015 Mar; 114(3):486. PubMed ID: 25877476 [No Abstract] [Full Text] [Related]
9. Tetrahydrobiopterin, its mode of action on phenylalanine hydroxylase, and importance of genotypes for pharmacological therapy of phenylketonuria. Heintz C; Cotton RG; Blau N Hum Mutat; 2013 Jul; 34(7):927-36. PubMed ID: 23559577 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of quality of life in PKU before and after introducing tetrahydrobiopterin (BH4); a prospective multi-center cohort study. Demirdas S; Maurice-Stam H; Boelen CC; Hofstede FC; Janssen MC; Langendonk JG; Mulder MF; Rubio-Gozalbo ME; van Spronsen FJ; de Vries M; Grootenhuis MA; Bosch AM Mol Genet Metab; 2013; 110 Suppl():S49-56. PubMed ID: 24100246 [TBL] [Abstract][Full Text] [Related]
17. Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment. Levy H; Burton B; Cederbaum S; Scriver C Mol Genet Metab; 2007 Dec; 92(4):287-91. PubMed ID: 18036498 [TBL] [Abstract][Full Text] [Related]
18. [Differential diagnosis and therapy of various forms of hyperphenylalaninemia: facts and fiction]. Endres W Wien Klin Wochenschr; 1992; 104(16):503-9. PubMed ID: 1413808 [TBL] [Abstract][Full Text] [Related]
19. Corrigendum to "In vitro evaluation of 2-hydroxyalkylated β-cyclodextrins as potential therapeutic agents for Niemann-pick type C disease" [Mol. Genet. Metab. (2016) 214-219]. Kondo Y; Tokumaru H; Ishitsuka Y; Matsumoto T; Taguchi M; Motoyama K; Higashi T; Arima H; Matsuo M; Higaki K; Ohno K; Irie T Mol Genet Metab; 2017 Mar; 120(3):296-297. PubMed ID: 27733311 [No Abstract] [Full Text] [Related]
20. Optimising growth in phenylketonuria: current state of the clinical evidence base. Dokoupil K; Gokmen-Ozel H; Lammardo AM; Motzfeldt K; Robert M; Rocha JC; van Rijn M; Ahring K; Bélanger-Quintana A; MacDonald A Clin Nutr; 2012 Feb; 31(1):16-21. PubMed ID: 21959353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]